Skip to main content
Top
Published in: Clinical and Translational Oncology 7/2016

01-07-2016 | Research Article

Compliance to radiation therapy of head and neck cancer patients and impact on treatment outcome

Authors: B. C. Ferreira, P. Sá-Couto, M. C. Lopes, L. Khouri

Published in: Clinical and Translational Oncology | Issue 7/2016

Login to get access

Abstract

Aims

The aims of the study were to evaluate head and neck cancer (HNC) patient’s compliance to the planned radiation therapy (RT) using the department policy established in 2005 at IPOCFG and to estimate the impact on treatment outcome due to failure in receiving RT as prescribed.

Materials and methods

359 HNC patients irradiated from 2007 to 2013 were included in this study. Patient cohort was divided into Group 1: patients receiving RT as prescribed and Group 2: patients that interrupted or suspended RT. Group Tox is the subgroup of patients that interrupted RT due to toxicity or intercurrent disease. Number and causes for treatment interruptions were assessed. The cumulative incidence of locoregional control (LRC), disease-free survival (DFS) and overall survival for Groups 1 and 2 was determined. Cox regression was performed to investigate potential hazard factors and logistic regression was made to determine risk factors related to treatment interruptions.

Results

Major causes for treatment interruptions were toxicity plus intercurrent disease (41.7 %) and public holidays (30.1 %). 10.3 % of the patients interrupted 3–9 days. Significant differences in survival distributions of the LRC between Groups 1 and 2, of up to 19 %, were found in the subgroup of patients with N2–3 tumours, for post-operative RT and for concomitant RT. Treatment breaks larger than two days had an almost fourfold increased risk of poorer LRC and DFS.

Conclusions

Twin accelerators and treating on public holidays are effective measures minimizing RT breaks. For HNC, patient compliance is mostly limited by RT side-effects. Efforts to maintain RT biological effective dose in HNC must be always undertaken.
Appendix
Available only for authorised users
Literature
1.
go back to reference Suwinski R, Sowa A, Rutkowski T, Wydmanski J, Tarnawski R, Maciejewski B. Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. Int J Radiat Oncol Biol Phys. 2003;56(2):399–412.CrossRefPubMed Suwinski R, Sowa A, Rutkowski T, Wydmanski J, Tarnawski R, Maciejewski B. Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. Int J Radiat Oncol Biol Phys. 2003;56(2):399–412.CrossRefPubMed
2.
go back to reference Groome PA, O’Sullivan B, Mackillop WJ, Jackson LD, Schulze K, Irish JC, et al. Compromised local control due to treatment interruptions and late treatment breaks in early glottic cancer: population-based outcomes study supporting need for intensified treatment schedules. Int J Radiat Oncol Biol Phys. 2006;64(4):1002–12.CrossRefPubMed Groome PA, O’Sullivan B, Mackillop WJ, Jackson LD, Schulze K, Irish JC, et al. Compromised local control due to treatment interruptions and late treatment breaks in early glottic cancer: population-based outcomes study supporting need for intensified treatment schedules. Int J Radiat Oncol Biol Phys. 2006;64(4):1002–12.CrossRefPubMed
3.
go back to reference Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys. 2007;68(3):654–61.CrossRefPubMed Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys. 2007;68(3):654–61.CrossRefPubMed
4.
go back to reference Fowler JF. Biological factors influencing optimum fractionation in radiation therapy. Acta Oncol. 2001;40(6):712–7.CrossRefPubMed Fowler JF. Biological factors influencing optimum fractionation in radiation therapy. Acta Oncol. 2001;40(6):712–7.CrossRefPubMed
5.
go back to reference Garau M, Monné J, Serés MJ. Monfà Binefa C, Peraire Llopis M. Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays. Clin Transl Oncol. 2009;11(5):302–11.CrossRef Garau M, Monné J, Serés MJ. Monfà Binefa C, Peraire Llopis M. Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays. Clin Transl Oncol. 2009;11(5):302–11.CrossRef
6.
go back to reference Tarnawski R, Fowler J, Skladowski K, Swierniak A, Suwinski R, Maciejewski B, et al. How fast is repopulation of tumor cells during the treatment gap? Int J Radiat Oncol Biol Phys. 2002;54(1):229–36.CrossRefPubMed Tarnawski R, Fowler J, Skladowski K, Swierniak A, Suwinski R, Maciejewski B, et al. How fast is repopulation of tumor cells during the treatment gap? Int J Radiat Oncol Biol Phys. 2002;54(1):229–36.CrossRefPubMed
7.
go back to reference Andrade L, Pais M. Lopes MC unsheduled interruptions and prolongation of treatment time in radiotherapy—one year study. Radiother Oncol. 2005;76(Supp. 2):S79.CrossRef Andrade L, Pais M. Lopes MC unsheduled interruptions and prolongation of treatment time in radiotherapy—one year study. Radiother Oncol. 2005;76(Supp. 2):S79.CrossRef
8.
go back to reference Ferreira BC, Marques RV, Khouri L, Santos T, Sá-Couto P, Lopes MC. Assessment and topographic characterization of locoregional recurrences in head and neck tumours. Radiat. Oncol. 2015;10:41.CrossRefPubMedPubMedCentral Ferreira BC, Marques RV, Khouri L, Santos T, Sá-Couto P, Lopes MC. Assessment and topographic characterization of locoregional recurrences in head and neck tumours. Radiat. Oncol. 2015;10:41.CrossRefPubMedPubMedCentral
9.
go back to reference Grégoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, et al. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC. RTOG consensus guidelines. Radiother Oncol. 2003;69(3):227–36.CrossRefPubMed Grégoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, et al. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC. RTOG consensus guidelines. Radiother Oncol. 2003;69(3):227–36.CrossRefPubMed
10.
go back to reference Grégoire V, Eisbruch A, Hamoir M, Levendag P. Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol. 2006;79(1):15–20.CrossRefPubMed Grégoire V, Eisbruch A, Hamoir M, Levendag P. Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol. 2006;79(1):15–20.CrossRefPubMed
11.
go back to reference Ferreira BC, Lopes MC, Mateus J, Capela M, Mavroidis P. Radiobiological evaluation of forward and inverse IMRT using different fractionations for head and neck tumours. Radiat. Oncol. 2010;5:57. Ferreira BC, Lopes MC, Mateus J, Capela M, Mavroidis P. Radiobiological evaluation of forward and inverse IMRT using different fractionations for head and neck tumours. Radiat. Oncol. 2010;5:57.
12.
go back to reference Fesinmeyer MD, Mehta V, Blough D, Tock L, Ramsey SD. Effect of radiotherapy interruptions on survival in medicare enrollees with local and regional head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010;78(3):675–81.CrossRefPubMed Fesinmeyer MD, Mehta V, Blough D, Tock L, Ramsey SD. Effect of radiotherapy interruptions on survival in medicare enrollees with local and regional head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010;78(3):675–81.CrossRefPubMed
13.
go back to reference Zhao L, Wan Q, Zhou Y, Deng X, Xie C, Wu S. The role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinoma. Radiother Oncol. 2011;98(1):23–7.CrossRefPubMed Zhao L, Wan Q, Zhou Y, Deng X, Xie C, Wu S. The role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinoma. Radiother Oncol. 2011;98(1):23–7.CrossRefPubMed
14.
go back to reference Shaverdian N, Gondi V, Sklenar KL, Dunn EF, Petereit DG, Straub MR, et al. Effects of treatment duration during concomitant chemoradiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2013;86(3):562–8.CrossRefPubMed Shaverdian N, Gondi V, Sklenar KL, Dunn EF, Petereit DG, Straub MR, et al. Effects of treatment duration during concomitant chemoradiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2013;86(3):562–8.CrossRefPubMed
15.
go back to reference Cannon DM, Geye HM, Hartig GK, Traynor AM, Hoang T, McCulloch TM, et al. Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy. Head Neck. 2014;36(8):1120–5.CrossRefPubMed Cannon DM, Geye HM, Hartig GK, Traynor AM, Hoang T, McCulloch TM, et al. Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy. Head Neck. 2014;36(8):1120–5.CrossRefPubMed
Metadata
Title
Compliance to radiation therapy of head and neck cancer patients and impact on treatment outcome
Authors
B. C. Ferreira
P. Sá-Couto
M. C. Lopes
L. Khouri
Publication date
01-07-2016
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 7/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1417-5

Other articles of this Issue 7/2016

Clinical and Translational Oncology 7/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine